Takeda, Lundbeck announce availability of recently renamed Trintellix

DEERFIELD, Ill. and OSAKA, Japan — Takeda Pharmaceuticals and Lundbeck on Wednesday announced the availability of its Trintellix (vortioxetine). The once-daily oral medication is indicated to treat adults with major depressive disorder. 

 

The trade name of the drug was initially Brintellix when it was approved in September 2013 and FDA approved a name change to minimize patient confusion over similarly named medication in early May. 

 

Trintellix is available in 5-, 10- and 20-mg tablets.